Fifteen infants (aged 2-21 days at onset of infection) were treated with a new semi-synthetic aminoglycoside antibiotic, amikacin, in a daily dose of between 126 and 350 mg depending on weight. The causative organism in the majority of cases was E coli and the most common sites from which it was isolated were the nasal and umbilical regions. Fourteen of the infants were cured and no systemic or local reactions to the treatment were observed.
